Associate Director, Market Access AMNOG, Germany

Darum lohnt es sich

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The incumbent will partner with regional and global commercial, HEOR, and medical affairs teams to deliver launch activities by providing access insights, developing evidence‑based HTA, pricing & reimbursement dossiers and tools, engaging with market access and public affairs stakeholders as well as participating in pricing strategy activities, and drive the activities to deliver access results supporting the overall success of the product launches.

Responsibilities • Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for oncology products within the German healthcare system. • HTA & Pricing Filings: Lead preparation and submission of value dossiers, benefit assessments (e.g., AMNOG/G‑BA) and pricing negotiations with statutory health insurance decision makers (e.g., GKV‑SV). • Value Communication: Translate clinical and economic evidence into compelling value communications tailored for German payers. • External Stakeholder Engagement: Build and maintain strong relationships with key external stakeholders (payers, HTA authorities, policy influencers). • Cross‑Functional Collaboration: Work with Global and EU Region Market Access teams to align local access strategy with broader European and corporate objectives, especially in terms of aligning the European regulatory and JCA strategy and execution with local value dossier submission and pricing negotiation strategies. • Participation in negotiations with all levels of national payers. • Collaborate with internal functions to develop innovative pricing and value‑based contracting models to optimize the acceleration of reimbursement approvals. • Policy Monitoring: Monitor health policy developments, HTA processes and local reimbursement environments to inform strategy. • Drive access and value related projects such as landscape assessments, payer market research, payer advisory boards and general guidance on local strategies. • Development of outreach and engagement plan for key payers and their influencers creating and maintaining a strong network. • Participate in early access planning of new products and indications, drive launch readiness for multiple oncology assets.

Required Skills, Experience and Education • Advanced degree (e.g., PhD in Life Sciences, Pharmacy, Health Economics, Public Health). • 8+ years experience in market access, pricing, reimbursement or health economics (pharma/biotech/market access consulting). • Proven AMNOG/benefit assessment experience, with deep understanding of payer decision‑making in Germany. • Demonstrated success and experience supporting an oncology product pre‑launch, launch and post‑launch in Germany. • Demonstrated success in negotiating pricing and reimbursement conditions with public administrations and health authorities. • Strong stakeholder management and ability to collaborate with internal and external partners. • Excellent communication skills, both in person and virtual. • Scientific and solution‑orientated mindset and capability to move and execute in a rapidly changing, ambiguous environment. • Strong understanding of local healthcare systems, customer dynamics, and reimbursement environments. • Strong commercial and strategic acumen. • Willingness to travel nationally and internationally. • Proven leadership and people management capabilities; demonstrated success in small but fast growing, entrepreneurial commercial environment.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC‑6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC‑9805), a RAS(ON) G12D‑selective inhibitor; and RMC‑5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.

The Opportunity The Associate Director, Market Access, Germany is responsible for defining and executing the market access strategy to ensure timely, sustainable patient access to innovative oncology therapies.

Working closely with the Senior Director, Market Access, in Germany, this role helps to shape business strategies, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities.